Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's Lymphoma in Brazil

Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's Lymphoma in Brazil

Author Souza, Eni M. Autor UNIFESP Google Scholar
Baiocchi, Otavio C. G. Autor UNIFESP Google Scholar
Zanichelli, Maria A. Google Scholar
Alves, Antonio C. Autor UNIFESP Google Scholar
Assis, Marianne G. Autor UNIFESP Google Scholar
Eiras, Daniel P. Autor UNIFESP Google Scholar
Dobo, Cristine Autor UNIFESP Google Scholar
Oliveira, Jose S. R. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Brigadeiro State Hosp
Abstract Introduction: Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein Barr virus (EBV), which can be found in a latent pattern in Reed-Sternberg (RS) cells. However, the impact of the presence of EBV in RS cells and its prognosis are still controversial. We analysed the presence of EBV in RS cells and its influence in the clinical evolution of patients with cHL treated in two public hospitals in the city of São Paulo, Brazil.Materials and Methods: We selected 97 patients with cHL from 1994 to 2004. Patients were only included in this study if they had (1) >18 years, (2) negative HIV serology, (3) undergone similar chemotherapy protocols, (4) paraffin blocks available with enough material for systematic review and histological reclassification and for detection of EBV in RS cells by in situ hybridization and immunohistochemistry and (5) clinical, epidemiological and laboratorial parameters available after a thorough chart review.Results: EBV was identified in 52.5% of the cases. Mixed cellularity (MC) subtype was more common in EBV-related tumours (25.5%) (p =0.005). There was no difference on age, gender, stage and the presence of B symptoms between the two groups. the presence of EBV did not influence event free survival (EFS) (p =0.38) or overall survival (OS) (p = 0.80) with a median follow-up of 80 months.Conclusion: We demonstrate that the prevalence of EBV-related cHL in this Brazilian population is 52.5% and, that, the presence of EBV does not change the clinical evolution and OS of patients treated with similar chemotherapy protocols. Copyright (C) 2010 John Wiley & Sons, Ltd.
Keywords Hodgkins lymphoma
Epstein-Barr virus
prognostic
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Grant number FAPESP: 02/10290-1
FAPESP: 02/09994-4
Date 2010-09-01
Published in Hematological Oncology. Chichester: John Wiley & Sons Ltd, v. 28, n. 3, p. 137-141, 2010.
ISSN 0278-0232 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 137-141
Origin http://dx.doi.org/10.1002/hon.933
Access rights Closed access
Type Article
Web of Science ID WOS:000283102900005
URI http://repositorio.unifesp.br/handle/11600/32858

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account